Physician profile
Udit Agarwal
NPI 1568753606
$1,431.54
in general payments reported to CMS, 2019-2025
20 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $138 · 2022: $192 · 2023: $426 · 2024: $276 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $253.06 | 2019-2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $233.92 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $232.45 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $174.08 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $104.32 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $96.14 | 2020 | |
| Merck Sharp & Dohme LLC | $57.68 | 2023-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $36.42 | 2024 | Arcalyst |
| Lemaitre Vascular, INC. | $32.49 | 2025 | Hydro Lemaitre Valvulotome |
| Astrazeneca Pharmaceuticals LP | $30.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.35 | 2023 | Xarelto |
| United Therapeutics Corporation | $21.14 | 2024 | Tyvaso |
| Boston Scientific Corporation | $20.30 | 2022 | |
| Daiichi Sankyo INC. | $20.07 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $18.25 | 2025 | Evkeeza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.05 | 2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $14.41 | 2023 | Inpefa |
| Convatec INC. | $14.21 | 2025 | |
| Sanofi-Aventis U.S. LLC | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udit Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.